RIGI and hepatocellular carcinoma: Notably, local injection of intracholesterol-bound RIG-I si-cDCBLD2 significantly increased liver tumor sensitivity to sorafenib in a mouse model, indicating that siRNA-mediated regulation of cDCBLD2 has good clinical application potential for sorafenib-resistant HCC patients.